亚太结直肠筛查评分联合粪便DNA检测提高结直肠进展期肿瘤检出率
研究纳入2842名受试者,2439人计算亚太结直肠筛查(APCS)评分,2240人完成粪便DNA检测(SDC2和SFRP2)、粪便免疫化学检测(FIT)及结肠镜。APCS联合粪便DNA检测检出95.2%的浸润性癌和73.5%的进展期肿瘤,结肠镜工作量仅47.1%。
要点
- APCS评分高危者占38.8%(946/2439),进展期肿瘤风险较低中危者增加1.8倍(95%CI 1.4-2.3)。
- APCS联合粪便DNA检测对进展期肿瘤灵敏度73.5%,显著高于联合FIT的62.8%(cut-off 20 μg/g)和68.0%(cut-off 4.4 μg/g),均P<.01。
- 联合策略检出95.2%浸润性癌(40/42),结肠镜工作量仅47.1%(1056/2240)。
核心结论
- APCS评分联合粪便DNA检测显著提高结直肠进展期肿瘤检出,同时限制结肠镜资源使用。
研究设计与样本
- 共纳入2842名就诊于门诊或癌症筛查中心的受试者,2439人计算APCS评分,2240人完成全部研究流程并以结肠镜为金标准。
- 粪便DNA检测采用SDC2和SFRP2检测,FIT同时使用4.4 μg/g阈值和厂商推荐的20 μg/g阈值以匹配粪便DNA检测的特异性。
主要发现
- APCS评分高危者占38.8%(946/2439),其进展期肿瘤风险较低危和中危者增加1.8倍(95%CI 1.4-2.3)。
- APCS联合粪便DNA检测检出95.2%的浸润性癌(40/42)和73.5%的进展期肿瘤(253/344),结肠镜工作量仅47.1%(1056/2240)。
- APCS联合粪便DNA检测对进展期肿瘤的灵敏度显著高于APCS联合FIT:73.5% vs 62.8%(FIT cut-off 20 μg/g),73.5% vs 68.0%(FIT cut-off 4.4 μg/g),均P<.01。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The Asia-Pacific Colorectal Screening (APCS) scoring system was developed to stratify the risk of colorectal advanced neoplasm (AN). We aimed to evaluate the performance of the APCS score combined with a stool DNA test used for colorectal cancer screening. METHODS: A total of 2842 subjects who visited outpatient clinics or cancer screening centers were enrolled. Age, sex, smoking status, and family history were recorded and APCS scores were calculated in 2439 participants. A stool DNA test (SDC2 and SFRP2 tests) and fecal immunochemical test (FIT) were performed and colonoscopy was used as the gold standard among 2240 subjects who completed all study procedures. We used a threshold of 4.4 μg/g for the FIT, in addition to the manufacturer's recommended threshold of 20 μg/g to match the specificity of a stool DNA test. RESULTS: Based on the APCS score, 38.8% (946 of 2439) of the subjects were categorized as high risk, and they had a 1.8-fold increase in risk for AN (95% CI, 1.4-2.3) compared with low and moderate risk. The APCS combined with the stool DNA test detected 95.2% of invasive cancers (40 of 42) and 73.5% of ANs (253 of 344), while the colonoscopy workload was only 47.1% (1056 of 2240). The sensitivity for AN of APCS combined with stool DNA test was significantly higher than that of APCS combined with FIT (73.5% vs 62.8% with FIT cut-off value of 20 μg/g, and 73.5% vs 68.0% with FIT cut-off value of 4.4 μg/g; both P < .01). CONCLUSIONS: The APCS score combined with a stool DNA test significantly improved the detection of colorectal ANs, while limiting colonoscopy resource utilization (Chictr.org.cn, ChiCTR-DDD-17011169).
引用
- Xu J, Rong L, Gu F, et al. Asia-Pacific Colorectal Screening Score Combined With Stool DNA Test Improves the Detection Rate for Colorectal Advanced Neoplasms. Clin Gastroenterol Hepatol. 2022. PMID: 36113828. doi:10.1016/j.cgh.2022.09.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。